Market Intelligence, Pyroptosis Pathways, and High-Purity Reagents for Inflammatory Disease and Oncology Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CASP4 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CASP4 (p20/p10 subunits) / Full Length Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. E. coli or HEK293 expressed. |
View CASP4 Products |
| Gene Delivery | CASP4 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Ideal for cell-based pyroptosis assays. |
View CASP4 Products |
| Benchmark Ab | Anti-CASP4 Antibody Recombinant positive control for Western Blot and Flow Cytometry. |
View CASP4 Products |
| Validator | CASP4 siRNA Set For knockdown verification and specificity assays. |
View CASP4 Products |
| Related Target A | GSDMD (Gasdermin D) Downstream substrate cleaved by active CASP4 to execute cell pyroptosis. |
View GSDMD Products |
| Related Target B | CASP1 (Caspase-1) Canonical inflammasome partner; critical for subfamily off-target counter-screening. |
View CASP1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native Active Heterodimer Conformation | Co-expressed p20 and p10 active subunits forming the functional complex, sequence verified. |
| CASP1/5 Subfamily Cross-Reactivity | Homolog panel proteins (CASP1, CASP5) strictly verified by mass spectrometry for counter-screening. |
| Intracellular Target Access & Verification | Lentivirus for stable overexpressing cell lines to support cell-based pyroptosis assays. |
| Off-Target Activity Verification | Validated siRNA set and benchmark antibodies included for assay specificity controls. |
Live CASP4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CASP4 therapeutics is intensifying, with major players shifting focus from traditional broad-spectrum caspase inhibitors to highly selective non-canonical inflammasome modulators. As first-generation systemic anti-inflammatory therapies reach the clinic, the next wave of R&D is targeting CASP4-mediated pyroptosis in specific contexts, such as acute sepsis, inflammatory bowel disease (IBD), and immunogenic cell death (ICD) in solid tumors.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Novartis, Pfizer, Inflammasome Biotechs | Sepsis, Inflammatory Bowel Disease (IBD) | Enzymatic activity assays (Need active p20/p10 heterodimer complex) |
| PROTAC / Degraders | Targeted Protein Degradation Biotechs | Autoimmune Diseases | Target engagement and ubiquitination assays (Need high-purity full-length CASP4) |
| Small Molecule Activators | Immuno-oncology Therapeutics | Refractory Solid Tumors (ICD induction) | Cell-based pyroptosis assays (Need Lentivirus for stable GSDMD/CASP4 cell lines) |